Search results
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data
FierceBiotech· 10 hours agoBiogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the...
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
Market Watch· 5 hours ago“However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a...
Biogen, Ionis shelve ALS drug following study failure
BioPharma Dive via Yahoo Finance· 11 hours agoWhile results indicated the drug works as intended, it didn’t have enough of an effect on a protein...
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic...
WFRV 5 Green Bay· 12 hours agoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO ...
Biogen and Ionis halt ALS drug development after trial setback By Investing.com
Investing.com· 10 hours agoBiogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have announced the...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 7 hours agoPerformance The Nasdaq Biotechnology Index has moved up 2.32% in the past five trading sessions and ...
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Medical Device Network via Yahoo Finance· 4 days agoThe approval of several drugs for Alzheimer’s such as Eisai’s Leqembi (lecanemab) and Biogen’s...
Is Eli Lilly Stock A Buy Or A Sell With Key Alzheimer's Meeting Looming?
Investor's Business Daily· 1 day agoThe decision effectively pushes back the approval decision, which was expected in the first quarter....
Eisai sets new revenue target for Alzheimer’s drug Leqembi
BioPharma Dive via Yahoo Finance· 1 day agoThe annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoNEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference
